Martin "Marty" Sands

About Marty Sands

Martin 'Marty' Sands is co-founder, chairman or CEO of multiple companies, including Genesis Merchant Partners, Frozen Food Partners, Paleo Passion Foods - Just Real Foods, and Optmed. Martin began his career working at several leading investment banks, including Shearson Lehman and Oppenheimer and Company, until launching his own firm in 1990. Shortly after launching this firm with his brother Steven, the firm became a New York Stock Exchange member firm, and grew to develop both an international as well as a domestic full-service investment business.

STUDY: Sugar Is As Addictive As Cocaine & Heroin

We've grown up on it. As we've grown older we've seen its effects. Kids running around at birthday parties and Halloween on "sugar highs." But is this just a clever play on words, or are people actually getting high on sugar? Well, it may be one addiction that won't land you in court or an [...]

Greenwich Magazine Interview’s Martin Sands

Martin Sands, Co-Founder and CEO of Paleo Passion Foods recently sat down with Greenwich Magazine to discuss his passion for healthy eating, food education and the killer in disguise, lurking in everyone's cupboard.

Greenwich Company Hits Whole Foods Market with Paleo-Diet Friendly Ice Pops

Nothing says "refreshing dessert" quite like kale, right? OK, maybe not. But one Greenwich company is hoping to change that with its new line of ice pops. "Kale is the hottest buzzword going right now, but it's kind of disgusting," said Marty Sands, founder and CEO of Paleo Passion Pops. "But we made kale delicious [...]

Paleo Passion Foods Launches Natural Ice Pops with No Added or Processed Sugar

Paleo Passion Pops offer health-conscious consumers a chance to enjoy a frozen treat without added chemicals and processed sugars. The all-natural ice pop uses fruit to provide a sweet, refreshing and healthy snack.

OptMed Completes Enrollment For First Phase of Clinical Study

NEW YORK (December 17, 2012)--- OptMed Inc., a specialty healthcare product development company, announced the completion of its required 30 patient enrollment for the first phase of a multicenter, prospective, open-label, randomized clinical study to evaluate BondEaseTM Topical Skin Adhesive.

2018-05-30T11:59:37-04:00Tags: , , |